Track IPSC and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$193.89M
Enterprise Value$66.15M
Revenue (TTM)$109.16M
Net Income (TTM)-$107.78M
Free Cash Flow (TTM)-$95.91M
Financial Health
Cash$134.80M
Net Debt-$127.74M
Debt Ratio0.02
Debt to Equity0.03
Interest Coverage-
Valuation (TTM)
Price to Sales1.78
Price to Earnings-1.8
EV to EBITDA-0.65
Price to Book0.73
Price to Free Cash Flow-2.02
Margins (TTM)
Gross Profit Margin90.95%
EBITDA Margin-1.78%
Operating Income Margin-13.78%
Net Income Margin-8.78%
Free Cash Flow Margin-95.92%
Returns (5Y Avg)
Return on Invested Capital-38.96%
Return on Assets-27.35%
Return on Equity-45.17%
Return on Total Capital-38.96%
Return on Capital Employed-32.75%
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue1000.00%
Diluted EPS9.65%
Total Debt-19.64%
Capital Expenditures-38.73%
Free Cash Flow-18.80%
CAGR (3Y)
Revenue175.88%
Diluted EPS45.11%
Total Debt-32.31%
Capital Expenditures-69.74%
Free Cash Flow-60.99%
CAGR (1Y)
Revenue1000.00%
Diluted EPS149.86%
Total Debt-31.75%
Capital Expenditures450.65%
Free Cash Flow1000.00%
$2.24+$0.05|+2.28%
52W High$3.04
52W Low$0.43
50D SMA$2.27
200D SMA$1.70
Volume704.50K
Century Therapeutics Inc
25 North 38th Street, Philadelphia, PA, United States, 19104
IPO
2021
Employees
78
Industry
Biotechnology
Sector
Healthcare
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 20264-4
0
Q4 20255-2
3
Q3 20253-3
0
Q2 20255-5
0
4-quarter cumulative
17 sells3 buys
Analyst Ratings
3 analysts covering
Buy67%recommend buy
Buy
2
Hold
1
Sell
0